Demographic and baseline characteristics for patients in INFAST Part 2 (all randomised patients)
| Patient characteristics at baseline of INFAST Part 1 (week 0) | NPX | No treatment |
|---|---|---|
| Baseline demographic characteristics | N=41 | N=41 |
| Gender (male), n (%) | 34 (82.9) | 30 (73.2) |
| Age (years), mean (SD) | 29.3 (7.02) | 29.5 (7.82) |
| Race, n (%) | ||
| White | 31 (75.6) | 38 (92.7) |
| Asian | 10 (24.4) | 3 (7.3) |
| Body mass index (kg/m2), mean (SD) | 23.6 (3.52) | 23.3 (4.19) |
| Clinical characteristics at baseline of INFAST Part 2 (week 28) | N=41 | N=41 |
| TJC68, mean (SD) | 0.2 (0.95) | 0.1 (0.40) |
| SJC66, mean (SD) | 0.0 (0.00) | 0.0 (0.16) |
| Patient Global Assessment of Disease Activity (0–100 mm), mean (SD) | 5.7 (5.82) | 5.7 (6.63) |
| Back pain (0–100 mm), mean (SD) | 6.1 (5.64) | 6.5 (6.69) |
| Physician Global Assessment of Disease Activity (0–100 mm) | 8.9 (8.61) | 8.7 (8.72) |
| Chest expansion (cm) | 5.5 (1.64) | 5.4 (1.97) |
| BASDAI (10 cm VAS), mean (SD) | 0.7 (0.66) | 0.6 (0.70) |
| BASMI, (10 cm VAS), mean (SD) | 1.5 (1.05) | 1.7 (1.13) |
| BASFI (10 cm VAS), mean (SD) | 0.6 (0.60) | 0.7 (1.00) |
| CRP (mg/dl), mean (SD) | 0.39 (0.786) | 0.58 (0.747) |
| ESR (mm/h), mean (SD) | 7.2 (8.25) | 9.1 (8.27) |
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; INFAST, Infliximab as First-Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial; NPX, naproxen; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.